Seaport Therapeutics

Seaport Therapeutics is a clinical-stage therapeutics company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The company utilizes its proprietary Glyph™ technology platform to enhance oral bioavailability and reduce side effects. Led by an experienced team, Seaport is committed to transforming the treatment of neuropsychiatric disorders and improving patients’ lives.